Cagrilintide / Retatrutide

Retatrutide Combination Therapy The Cagrilintide / Retatrutide Combination provides a dualmechanism strategy for weight management and metabolic health. Cagrilintide – a long-acting amylin analog (half-life ~165 hours) that enhances satiety, slows gastric emptying, and suppresses postprandial glucagon via brainstem amylin receptor activation. Retatrutide – a triple agonist of GLP-1, GIP, and glucagon receptors (half-life ~6 days), promoting insulin secretion, hepatic fat oxidation, appetite suppression, and energy expenditure. Together, they target both homeostatic and hedonic eating pathways, improve glucose regulation, and drive fat loss through complementary metabolic mechanisms.